Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > First THC Based Prescription Drug, Huge Milestone for TBP

<< Previous

Bullboard Posts

Next >>

Post by Savage97on Mar 11, 2022 9:46am

229 Views

Post# 34506155

First THC Based Prescription Drug, Huge Milestone for TBP

Dronabinol Soft Gel capsules New Drug Submission (NDS) file was submitted to Health Canada on December 30, 2020, a successful application will provide Tetra with its first Drug Identification Number (DIN) for a THC-based prescription drug. The Canadian market is estimated to be $80M CDN by 2022. The launching of REDUVO™ moves the Company from a pre-revenue biotech to in revenue. TBP anticipates strong demand for the only THC-based drug in Canada that will be publicly reimbursed by provinces and territories in Canada. QIXLEEF next DIN. $$$